NASDAQ:STIMNeuronetics Stock Price, Forecast & News

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STIM shares have decreased by 2.9% and is now trading at $2.01. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neuronetics.

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Neuronetics.

Neuronetics Inc (NASDAQ:STIM) announced its earnings results on Tuesday, May, 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.13. The firm had revenue of $11.48 million for the quarter. Neuronetics had a negative return on equity of 68.77% and a negative net margin of 55.58%. View Neuronetics' earnings history.

Neuronetics updated its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.8-12 million, compared to the consensus revenue estimate of $13.77 million.

4 equities research analysts have issued 1-year price objectives for Neuronetics' shares. Their forecasts range from $4.00 to $6.00. On average, they expect Neuronetics' share price to reach $5.33 in the next year. This suggests a possible upside of 165.3% from the stock's current price. View analysts' price targets for Neuronetics.

Press coverage about STIM stock has trended positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neuronetics earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutNeuronetics.

Neuronetics saw a increase in short interest in May. As of May 15th, there was short interest totaling 704,900 shares, an increase of 10.3% from the April 30th total of 639,000 shares. Based on an average trading volume of 322,400 shares, the short-interest ratio is presently 2.2 days. Approximately 6.6% of the shares of the stock are short sold. View Neuronetics' Current Options Chain.

Some companies that are related to Neuronetics include BeyondAirInc . (XAIR), RenovaCare (RCAR), Spectral Medical (EDTXF), PAVmed (PAVM), Venus Concept (VERO), BRAINSWAY LTD/S (BWAY), T2 Biosystems (TTOO), SANUWAVE Health (SNWV), AIT Therapeutics (AITB), Pro-Dex (PDEX), Nephros (NEPH), Nephros (NEPHD), Apollo Endosurgery (APEN), STRATA Skin Sciences (SSKN) and Motus GI (MOTS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS), Nokia Oyj (NOK), Novavax (NVAX) and Onconova Therapeutics (ONTX).

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Neuronetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.81%), DAFNA Capital Management LLC (2.65%), Quinn Opportunity Partners LLC (2.55%), State Street Corp (1.24%), Two Sigma Investments LP (1.10%) and JPMorgan Chase & Co. (1.03%). Company insiders that own Neuronetics stock include Brian E Farley, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Peter Donato, Stephen Furlong, Stephen M Campe, Wilfred E Jaeger and William Andrew Macan. View institutional ownership trends for Neuronetics.

STIM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Alambic Investment Management L.P., Deutsche Bank AG, and Spark Investment Management LLC. View insider buying and selling activity for Neuronetics.

STIM stock was bought by a variety of institutional investors in the last quarter, including Quinn Opportunity Partners LLC, Two Sigma Investments LP, Two Sigma Advisers LP, DAFNA Capital Management LLC, Blair William & Co. IL, JPMorgan Chase & Co., GSA Capital Partners LLP, and BlackRock Inc.. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Stephen Furlong, Stephen M Campe, Wilfred E Jaeger, and William Andrew Macan. View insider buying and selling activity for Neuronetics.

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STIM stock can currently be purchased for approximately $2.01.

Neuronetics has a market capitalization of $37.65 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe.

The official website for Neuronetics is www.neurostar.com.

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]